C4 Therapeutics (CCCC) Common Equity (2019 - 2026)

C4 Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $234.2 million for Q1 2026.

• On a quarterly basis, Common Equity rose 20.04% year-over-year to $234.2 million in Q1 2026; TTM through Mar 2026 was $234.2 million, a 20.04% increase from a year earlier, with the FY2025 full-year figure at $256.6 million, up 18.8% from the prior year.
• Common Equity eased to $234.2 million in Q1 2026 per CCCC's latest filing, from $256.6 million in the prior quarter.
• Across five years, Common Equity topped out at $364.5 million in Q1 2022 and bottomed at $154.4 million in Q3 2025.
• The 5-year median for Common Equity is $246.1 million (2023), against an average of $250.2 million.
• Across the five-year window, Common Equity soared 38.23% in 2022 and plunged 36.37% in 2025, its largest moves.
• Year by year, Common Equity stood at $289.2 million in 2022, then dropped by 14.91% to $246.1 million in 2023, then dropped by 12.24% to $216.0 million in 2024, then climbed by 18.8% to $256.6 million in 2025, then dropped by 8.71% to $234.2 million in 2026.
• Per Business Quant, the three latest CCCC Common Equity figures stand at $234.2 million (Q1 2026), $256.6 million (Q4 2025), and $154.4 million (Q3 2025).